R&D channel feed

Ab­b­Vie, Scripps ex­pand part­ner­ship, for­ti­fy fo­cus on can­cer drugs

6 years ago
Deals

Paul Hud­son promis­es a bright new fu­ture at Sanofi, kick­ing loose me-too drugs and fo­cus­ing on land­mark ad­vances. But can he de­liv­er?

6 years ago

Sanofi’s big week in­cludes a promis­ing PhI­II for an or­phan dis­ease drug, with plans for a pitch to the FDA

6 years ago

In­scrip­ta push­es fund­ing to $260 mil­lion as they launch genome edit­ing plat­form

6 years ago

Sanofi CEO Hud­son lays out new R&D fo­cus — chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal dis­sec­tion

6 years ago

Game on: Re­gen­eron's BC­MA bis­pe­cif­ic makes clin­i­cal da­ta de­but, kick­ing off mul­ti­ple myelo­ma matchup with Bris­tol-My­ers

6 years ago

FDA lifts hold on Abeon­a's but­ter­fly dis­ease ther­a­py, paving way for piv­otal study

6 years ago
FDA+

Roche faces an­oth­er de­lay in strug­gle to nav­i­gate Spark deal past reg­u­la­tors — but this one is very short

6 years ago

KalVis­ta's di­a­bet­ic mac­u­lar ede­ma da­ta falls short — will Mer­ck walk away?

6 years ago

#ASH19: Here’s why Mer­ck is pay­ing $2.7B to­day to grab Ar­Qule and its next-gen BTK drug, lin­ing up Eli Lil­ly ri­val­ry

6 years ago

Ob­sE­va makes case for hor­mone sup­pres­sive ther­a­py in uter­ine fi­broid study, but safe­ty qualms vex in­vestors

6 years ago

Bris­tol-My­ers is mak­ing a bee-line to the FDA with pos­i­tive liso-cel da­ta — but is it too late in the CAR-T game?

6 years ago
Cell/Gene Tx

Pa­tient #9 has been a con­cern, but Sang­amo and Pfiz­er are bull­ish about win­ning the marathon he­mo­phil­ia A gene ther­a­py race

6 years ago
Cell/Gene Tx

J&J team shows off 'break­through' BC­MA CAR-T da­ta, and that could cause a big headache at blue­bird and Bris­tol-My­ers

6 years ago
Cell/Gene Tx

UCB buffs up in block­buster pso­ri­a­sis race as bimek­izum­ab beats Hu­mi­ra in head-to-head

6 years ago

With EMA re­view in progress, No­var­tis un­veils more pos­i­tive da­ta on asth­ma ther­a­py

6 years ago

With FDA re­view of its gene ther­a­py un­der­way, Fer­ring's $570M spin­out de­liv­ers in PhI­II blad­der can­cer read­out

6 years ago
Cell/Gene Tx

On the heels of a PhI­II im­plo­sion, can­cer biotech Molo­gen is turned over to the liq­uida­tor

6 years ago

The fu­ture of Ipsen’s new $1.3B drug is in doubt as safe­ty fears force the FDA to slam the brakes on late-stage stud­ies

6 years ago
FDA+

Skep­tics pounce as Bio­gen de­tails pos­i­tive sub­group analy­sis on ad­u­canum­ab — and both sides are dig­ging in

6 years ago

Vivek Ra­maswamy’s En­zy­vant is hit with a CRL for man­u­fac­tur­ing — de­lay­ing a new ther­a­py for an ul­tra-rare killer

6 years ago

Daphne Koller's AI start­up ends wide search for a da­ta chief, tap­ping Stan­ford's Ser­afim Bat­zoglou for the job

6 years ago

No­var­tis CEO Vas Narasimhan's R&D up­date spot­lights next wave of drug stars as well as late-stage fa­vorites

6 years ago

Michael Ehlers teas­es plan to build the next 'sig­na­ture' ge­net­ic med­i­cine com­pa­ny with $75M from Ap­ple Tree Part­ners

6 years ago
First page Previous page 219220221222223224225 Next page Last page
A service from the Financial Times